Efficacy News and Research

RSS

International research explains why measles virus spreads so quickly

An international collaboration involving Inserm has revealed how the measles virus leaves the body of an infected person to contaminate another individual. The researchers have identified a key receptor, located in the trachea, which allows the virus to spread through the air rapidly from one organism to another. The receptor, nectine-4, is also known to be a biomarker for some cancers.

5 Nov 2011

Phase III study of BG-12 in relapsing-remitting multiple sclerosis sparks excitement

Citeline, an Informa business unit, and the world's leading research authority on pharmaceutical clinical trials recently reviewed results presented at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, a major multiple sclerosis conference which was held October 19-22, 2011 in Amsterdam.

5 Nov 2011

Chemotherapy plus radiation improves overall survival for patients with stage II NPC

The combination of chemotherapy and radiation significantly improved the 5-year overall survival of patients with stage II nasopharyngeal carcinoma (NPC), according to a phase III study published Nov. 4 in the Journal of the National Cancer Institute.

5 Nov 2011

Janssen receives FDA approval for Xarelto to prevent stroke in people with AF

The U.S. Food and Drug Administration today approved the anti-clotting drug Xarelto (rivaroxaban) to reduce the risk of stroke in people who have abnormal heart rhythm.

5 Nov 2011

Rexahn announces results from Serdaxin Phase IIb trial on major depressive disorder

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced results from its Phase IIb clinical trial of Serdaxin in major depressive disorder.

5 Nov 2011

Positive data from RegeneRx RGN-259 Phase 2 trial on dry eye syndrome

RegeneRx Biopharmaceuticals, Inc. today announced positive data from its 72-patient, Phase 2 clinical trial with RGN-259, a sterile, preservative-free eye drop, to evaluate its safety and efficacy for the treatment of signs and symptoms of dry eye syndrome over a treatment period of 30 days using the Controlled Adverse Environment (CAE) model.

5 Nov 2011

GTx third quarter net loss increases to $9.3 million

GTx, Inc. today reported financial results for the third quarter of 2011. The net loss for the quarter ended September 30, 2011 was $9.3 million compared with a net loss of $8.6 million for the quarter ended September 30, 2010, reflecting increased research and development costs in connection with the Company's Ostarine™ and Capesaris™ clinical development programs.

4 Nov 2011

Positive results from Clinuvel's US Phase II study of photoprotective drug, afamelanotide

Clinuvel Pharmaceuticals Limited, a global biopharmaceutical company with unique expertise on the interaction of light and human skin, today announced positive results of its first US Phase II study of the novel photoprotective drug afamelanotide, known as SCENESSE.

3 Nov 2011

Abbott to highlight latest research findings on HUMIRA at ACR annual meeting

Abbott scientists and independent researchers will highlight the latest research findings on HUMIRA (adalimumab) at this year's American College of Rheumatology (ACR) Annual Scientific Meeting, scheduled for November 5-9 in Chicago.

3 Nov 2011

Novel indirect screener can identify women at risk for illicit drug use

A team of researchers at Wayne State University's Parent Health Lab in the School of Medicine have developed a novel indirect screener that identifies women at risk for drug use by evaluating correlates of illicit drug use rather than drug use itself. In phase I testing, this new screener proved to be more sensitive than any alternative approach at detecting recent drug use.

3 Nov 2011

FEIBA drug safe and effective for patients with hemophilia A

An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, has found that a drug commonly used to treat bleeding events in people with a type of severe hemophilia can also be used to prevent such events from happening in the first place.

3 Nov 2011

MSCs can be reprogrammed to have enhanced survival and therapeutic efficacy

Chinese stem cell scientists have published new research that improves the survival and effectiveness of transplanted stem cells. The research led by Dr Hsiao Chang Chan, from the Chinese University of Hong Kong, is published in Stem Cells.

3 Nov 2011

Promedior's Pentraxin-2 effectively suppresses liver fibrosis

Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic, inflammatory and neovascular diseases, today announced that data from preclinical studies of Serum Amyloid P (Pentraxin-2) will be presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2011), being held November 4-8, 2011, in San Francisco, CA.

3 Nov 2011

Viewpoints: GOP intransigence on super committee; taxing health benefits would backfire; the need for care in defining essential benefits

There may be logic to Speaker John Boehner's insidious intransigence. Republicans keep saying no and Democrats keep offering more concessions. Super committee Republicans suggested instead a package based largely on cuts in Medicare, Medicaid and Social Security, combined with magical hundreds of billions they say would be produced by slashing assistance to the elderly and the vulnerable, by selling off government assets, and by the growth sparked by tax cuts.

3 Nov 2011

AVEO third quarter net loss increases to $23.8 million

AVEO Pharmaceuticals, Inc. today reported consolidated financial results for the third quarter of 2011 and provided an update on the tivozanib clinical program.

2 Nov 2011

NovaSterilis reports significant findings from sterilization of absorbable suture study

NovaSterilis Inc. a leader in the development and commercialization of supercritical carbon dioxide (SCCO2) technology in collaboration with CC Chu Ph.D (Cornell) reports successful findings from research funded by a National Institutes of Health (NIH) phase l grant. These results meet the study goal to sterilize absorbable sutures to a sterility assurance level 10-6 (SAL6) without chemical or mechanical degradation. NovaSterilis intends to apply for phase II funding to develop the process ready for commercial application.

1 Nov 2011

Pharmasset initiates PSI-7977 Phase 3 program for HCV

Pharmasset, Inc. today announced the initiation of a Phase 3 program with the hepatitis C virus (HCV) nucleotide analog, PSI-7977. This pivotal program will evaluate a 12-week, all-oral, interferon-free regimen of PSI-7977 and ribavirin in patients with HCV, independent of viral genotype or their ability to take interferon therapy.

1 Nov 2011

Ultra-sensitive techniques for early detection of breast cancer

A team of scientists at Tufts University will develop ultra-sensitive techniques at the single-molecule and single-cell levels designed to detect breast cancer earlier, and treat it with greater precision, through a $6.6 million Innovator Award from the Department of Defense Breast Cancer Research Program made to Tufts chemist David R. Walt, Ph.D.

1 Nov 2011

BUSM professor delivers Van Meter Award Lecture at 81st ATA meeting

The American Thyroid Association (ATA) is proud to announce that Dr. Elizabeth Pearce, Associate Professor of Medicine at Boston University School of Medicine, today delivered the Van Meter Award Lecture at its 81st Annual Meeting, held October 26-30, Indian Wells, California.

1 Nov 2011

Studies on effectiveness of new HCV therapies presented at 76th ACG meeting

Studies reporting on the effectiveness of new therapies for chronic Hepatitis C virus are among the clinical science presented at the American College of Gastroenterology's 76th Annual Scientific Meeting, where investigators also presented findings from an age-based risk assessment and screening intervention for Hepatitis C among Baby Boomers, patients aged 50-65, who saw a gastroenterologist for routine colon cancer screening.

1 Nov 2011